{"id":10728,"date":"2026-10-30T22:37:30","date_gmt":"2026-10-30T19:37:30","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10728"},"modified":"2026-10-30T22:37:30","modified_gmt":"2026-10-30T19:37:30","slug":"tavr-for-native-ar-2026","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/tavr-for-native-ar-2026\/","title":{"rendered":"TAVR for Native AR \u2014 2026"},"content":{"rendered":"<p>TAVR for Native AR \u2014 2026<\/p>\n<p>Source: ACC\/SCAI\/STS Joint Statement<br \/>\n\u2022\u2060 \u2060ACC\/SCAI\/STS support Medicare coverage for appropriately selected patients.<br \/>\n\u2022\u2060 \u2060AVR: Class I for symptomatic severe AR; also if asymptomatic with LVEF \u226455%.<br \/>\n\u2022\u2060 \u2060SAVR remains standard in operable patients.<br \/>\n\u2022\u2060 \u2060JenaValve Trilogy: first FDA-approved TAVR device for symptomatic severe native AR.<br \/>\n\u2022\u2060 \u2060Require Heart Team + multimodality imaging + FDA-approved device + registry follow-up.<br \/>\n\u2022\u2060 \u2060Evidence remains limited: ~1,500 native-AR TAVR patients vs ~1 million TAVR for AS.<\/p>\n<p>Bottom line: TAVR is now an emerging option for selected symptomatic severe native AR; SAVR remains the established standard.<br \/>\n\u2022\u2060 \u2060Evidence still limited: ~1,500 native-AR TAVR patients vs ~1 million TAVR for AS.<\/p>\n<p>Bottom line: TAVR is emerging as a dedicated option for selected severe symptomatic native AR patients; SAVR remains the established standard.<\/p>\n<p><a href=\"https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2026\/09\/11\/18\/54\/acc-sts-and-scai-issue-joint-statement-on-tavr-national-coverage-determination\">https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2026\/09\/11\/18\/54\/acc-sts-and-scai-issue-joint-statement-on-tavr-national-coverage-determination<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TAVR for Native AR \u2014 2026 Source: ACC\/SCAI\/STS Joint Statement \u2022\u2060 \u2060ACC\/SCAI\/STS support Medicare coverage for appropriately selected patients. \u2022\u2060 \u2060AVR: Class I for symptomatic severe AR; also if asymptomatic with LVEF \u226455%. \u2022\u2060 \u2060SAVR remains standard in operable patients. \u2022\u2060 \u2060JenaValve Trilogy: first FDA-approved TAVR device for symptomatic severe native AR. \u2022\u2060 \u2060Require Heart [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10728","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10728"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10728\/revisions"}],"predecessor-version":[{"id":10729,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10728\/revisions\/10729"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}